MACUSTAR is an observational clinical study with 20 participating clinical study sites across Europe. Over 700 patients have been recruited and are being reviewed for a period of up to three years. The study data are being analyzed to develop and validate appropriate clinical endpoints for future clinical trials and drug development in intermediate age-related macular degeneration (AMD).
The MACUSTAR project is a unique public-private partnership supported by the Innovative Medicines Initiative and combines Europe’s most relevant clinical and scientific expertise. The MACUSTAR consortium consists of 13 partners including leading academic centres, research-focused eye hospitals, research organizations and major medical-technology and pharmaceutical companies.
UCL are the academic lead for the study of visual function within MACUSTAR, working closely with European partners including the University of Bonn, Germany; City, University of London; F. Hoffmann-La Roche Ltd (ROCHE) Basel, Switzerland; Novartis Pharma AG (Novartis) Basel, Switzerland and the Association for Innovation and Biomedical Research on Light and Image (AIBILI) Coimbra, Portugal.
MACUSTAR is now closed to patient recruitment and is in its follow up period.
For more information on MACUSTAR please see our study website: https://www.macustar.eu